Dr. Xiaobing Qian received her MD degree from Peking University Medical School, and her PhD degree in Biochemistry and Molecular Biology from University of Illinois College of Medicine, Chicago. She conducted her postdoctoral research at the Gladstone Institutes at the University of California, San Francisco. Dr. Qian is a member of the TRIUM Global EMBA Class 2024, a premier program delivered by NYU Stern/London School of Economics/Paris HEC.
Dr. Qian brings to Degron more than 20 years of extensive biopharmaceutical experience in drug discovery, preclinical and clinical development, and business strategy, as well as expertise in empowering and leading multidisciplinary teams.
Prior to joining Degron Therapeutics, Dr. Qian served as VP Clinical Development and VP Global Medical Evaluations & Strategy at Boston Pharmaceuticals, she led the successful completion of clinical programs and was the clinical member of the BD diligence team that evaluated more than 300 programs and closed 5 deals in 12 months. Dr. Qian was Executive Director, Early Clinical Development and Head Translational Medicine Strategy and Medical Director at Regeneron Pharmaceuticals from 2008-2018, where she demonstrated her extensive expertise and successfully led efforts to identify new product opportunities through integrated scientific, medical, and clinical/regulatory development analysis across multiple therapeutic areas. She and her team helped advance more than 20 drug candidates into clinical development and 6 marketed drugs. Dr. Qian was also a Medical Director of two clinical programs at Regeneron Pharmaceuticals and led First in Human and proof of concept clinical trials globally. While working at CGI Pharmaceuticals, Dr. Qian led the discovery and development of several kinase inhibitor drugs in oncology and autoimmune diseases, and contributed to multiple partnerships and funding successes, including a $500 million Genentech/CGI BTK collaboration. Dr. Qian is also a pioneering scientist and inventor of AAV gene therapy for hemophilia. She has multiple patents and publications from her innovative work in gene therapy, small molecule kinase inhibitors, and biological drugs.
“We are excited to have Dr. Xiaobing Qian join Degron in this crucial role as we enter the next phase of growth at Degron. Throughout her impressive career, Dr. Qian has amassed deep scientific knowledge and extensive translational and clinical expertise that make her the ideal leader to advance Degron’s lead programs into clinical stage. Degron aims to develop cutting-edge science and breakthrough medicines, and we’re thrilled to add Xiaobing to our leadership team to help us achieve this goal.” said Dr. Lily Zou, CEO of Degron.
“I am very impressed with the strong scientific foundation and molecular glue drug discovery technology platform at Degron Therapeutics. The company’s proprietary chemical library is uniquely enriched of drug-like molecules that degrade previously undruggable disease relevant targets. I am inspired by the creativity and tremendous focus and speed the team executed the discovery projects. I look forward to applying my experience to advance the development of the pipeline, and together with Degron colleagues, build a world class innovative biotech company to bring novel medicines to patients in need.” Said Dr. Xiaobing Qian, CDO of Degron.
Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening system to develop a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of preclinical compounds for oncology, inflammation, metabolic disease, and rare diseases.